Probiotics in Ankylosing Spondylitis: A Possible Potency

Sumartini Dewi (Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital,Bandung)
Stefanie Yuliana Usman (Sultan Muhammad Jamaludin 1 Regional General Hospital, North Kayong Regency, West Kalimantan)
Guntur Darmawan (Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung)
Dolvy Girawan (Division of Gastroentero-hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung)

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019

Ankylosing Spondylitis (AS) is a common autoimmune arthritis which prevalence ranging from 0.1% up to 1.4% globally. Furthermore, in Asian population the prevalence of AS was increasing overtime. Up until now, there were several treatment options available in treating AS in Indonesia. However, there was still some limitations in complete remission achievement and some have limitation in potential adverse drug reaction. Eventually, these affect both patients’s daily activity and their quality of life.There were studies demonstrated the association between intestinal dysbiosis and inflammatory rheumatic disorders. Previous studies also presented there was an altered composition of gut microbiota in AS patients. Probiotic in the other hand, has been known previously for its efficacy in treating intestinal dysbiosis. Hence, this review aimed to identify potencies, efficacy and safety of probiotics as AS treatment options.